Leveraging a breakthrough discovery from Stanford University, AcureX Therapeutics has developed a platform that identifies druggable targets responsible for impaired mitophagy, a process crucial for cell health. Their two small-molecule therapeutic programs reactivate mitophagy, protecting neurons derived from Parkinson's patients. With a proprietary biomarker that measures mitophagy in PD patients, AcureX's clinical development plan aims to provide early efficacy insights and personalized treatment options. This approach shows promise not only for Parkinson's but also for other diseases linked to mitophagy, expanding their market opportunities beyond neurodegeneration.